Bansisons Tea Industries Ltd (519353)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Bansisons Tea's revenue was ₹1.7 Cr, and net profit ₹-0.0 Cr (a bigger loss than a year earlier); the operating margin was -1.0%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹1.7 | — | — |
| Operating profit | ₹-0.0 | loss narrowed | loss narrowed |
| Net profit | ₹-0.0 | loss widened | loss narrowed |
| EPS (₹) | -0.03 | loss widened | loss narrowed |
| Operating margin | -1.0% | — | — |
📢 Recent Corporate Announcements
Bansisons Tea Industries Limited has officially received approval to change its corporate name to 'Novyra Pharmachem Limited' effective from January 19, 2026. The name change signals a business pivot from tea into pharmaceuticals, life sciences, API manufacturing, specialty chemicals, and CRO/CDMO services. The company is a micro-cap with a market capitalization of Rs 7 Cr, which reported FY26 revenue of Rs 0.1 Cr and a net loss of Rs -5.37 Cr. Investors should note that while the corporate identity has shifted, no concrete capital outlay, plant locations, or execution timelines were quantified in this filing.
- Corporate name changed from 'Bansisons Tea Industries Limited' to 'Novyra Pharmachem Limited'
- Approval received on 22 August 2026 pursuant to an application dated 16 July 2026
- Certificate of Incorporation issued by the RoC Central Processing Centre on 19 January 2026
- Pivoting operations into active pharmaceutical ingredients (APIs), bulk drugs, and CDMO/CRO services
Novyra Pharmachem (formerly Bansisons Tea Industries) reported standalone revenue from operations of ₹1.73 Cr (₹172.61 lakhs) for the quarter ended June 30, 2026, compared to ₹0.10 Cr in the preceding quarter and ₹0.03 Cr in Q1 FY26. Net loss narrowed substantially to ₹0.02 Cr (₹1.99 lakhs) from a loss of ₹5.34 Cr in Q4 FY26. Total revenue was entirely generated from the Pharma segment, while the legacy Tea Estate and Real Estate segments reported zero revenue. Basic and diluted EPS for the quarter stood at ₹(0.03).
- Revenue from operations rose to ₹1.73 Cr (₹172.61 lakhs) in Q1 FY27 from ₹0.10 Cr in Q4 FY26
- Net loss narrowed significantly to ₹0.02 Cr (₹1.99 lakhs) from ₹5.34 Cr in the preceding quarter
- Pharma segment contributed 100% of the operational revenue at ₹172.61 lakhs
- Quarterly EPS improved to ₹(0.03) compared to ₹(8.43) in Q4 FY26
Novyra Pharmachem Ltd (formerly Bansisons Tea Industries Ltd) reported standalone revenue from operations of Rs 1.73 Cr (Rs 172.61 lakhs) for the quarter ended June 30, 2026, compared to Rs 0.03 Cr in the year-ago period. The operational revenue was entirely driven by the Pharma business segment. Standalone net loss narrowed significantly to Rs 0.02 Cr (Rs 1.99 lakhs) from a net loss of Rs 5.34 Cr in the preceding quarter (Q4 FY26). Total expenses stood at Rs 1.75 Cr, primarily driven by stock-in-trade purchases of Rs 1.89 Cr.
- Standalone revenue from operations stood at Rs 172.61 lakhs for Q1 ended June 30, 2026 vs Rs 3.00 lakhs in Q1 ended June 30, 2025.
- Net loss sharply reduced to Rs 1.99 lakhs compared to a loss of Rs 533.83 lakhs in the preceding quarter.
- Pharma segment contributed the entirety of segment revenue at Rs 172.61 lakhs, with Real Estate and Tea segments generating nil revenue.
- Basic and diluted EPS stood at Rs -0.03 per share vs Rs -8.43 in Q4 FY26.
Novyra Pharmachem Limited (formerly Bansisons Tea Industries Ltd) has scheduled a board meeting for August 14, 2026, to approve unaudited financial results for the quarter ended June 30, 2026. The company is a micro-cap with a market capitalization of only ₹7 Cr and reported a significant net loss of ₹5.34 Cr in the March 2026 quarter. With TTM revenue at nearly zero and a net worth of just ₹1 Cr, the company's financial position is precarious. The name change suggests a potential shift from tea to the pharmaceutical/chemical sector, which investors should monitor for operational updates.
- Board meeting scheduled for August 14, 2026, to consider Q1 results.
- Company reported a net loss of ₹5.34 Cr in the previous quarter (March 2026).
- Market capitalization stands at a minimal ₹7 Cr with a net worth of ₹1 Cr.
- TTM revenue is effectively ₹0 Cr, indicating a lack of core operations in the recent past.
Bansisons Tea Industries Ltd has updated its official website to www.novyrapharmachemltd.com following its name change to Novyra Pharmachem Limited. This is a procedural update to comply with SEBI (LODR) Regulations. The company remains a micro-cap entity with a market capitalization of Rs 7 Cr and reported zero revenue for the TTM period. Investors should note the significant financial distress, with a TTM PAT of Rs -5 Cr and an operating margin of -5380%.
- Official website address changed from www.bansisonstea.com to www.novyrapharmachemltd.com
- Company name changed to Novyra Pharmachem Limited from Bansisons Tea Industries Ltd
- TTM Revenue stands at Rs 0 Cr as of the latest financial context
- TTM PAT is significantly negative at Rs -5 Cr
- Promoter holding remains stable at 23.15% as of March 2026
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
